Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 16.7% on Saturday . The company traded as low as C$0.10 and last traded at C$0.10. Approximately 670,435 shares changed hands during trading, an increase of 78% from the average daily volume of 376,657 shares. The stock had previously closed at C$0.12.
Hemostemix Trading Down 16.7%
The company has a 50-day simple moving average of C$0.13 and a 200-day simple moving average of C$0.15. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The stock has a market cap of C$14.57 million, a P/E ratio of -2.92 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- What is a buyback in stocks? A comprehensive guide for investors
- Why Teradyne’s 19% Rally Is Just Getting Started
- Upcoming IPO Stock Lockup Period, Explained
- Buy the Dip on 3 Overlooked Names With Major Potential
- Insider Trades May Not Tell You What You Think
- Bitcoin and Dividends: A Winning Combo in These 3 ETFs
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
